Long COVID & viral persistence - new evidence
A new study detected a peptide fragment specific to SARS-CoV-2 nsp3 in blood extracellular vesicles (EVs) from Long COVID patients - months to years after infection.
Let’s unpack why this matters.🧵
EVs are tiny membrane packages released by cells, carrying proteins, RNA, and lipids.
They can travel in blood, cross biological barriers, and deliver their contents to other cells - bypassing normal immune surveillance!
The detected peptide - GSLPINVIVFDGK - is uniquely part of nsp3, a large viral enzyme encoded by ORF1ab.
Nsp3 is crucial for SARS-CoV-2 replication and immune evasion.
Importantly - the study found the peptide, not necessarily the entire intact protein.
This nuance matters:
If it’s just a fragment, it might be biologically inert.
If it contains active domains, it could still disrupt host cell processes.
We don’t know which scenario applies here - but either way, it’s proof of viral material in long Covid circulation.
Results:
12/14 Long COVID patients had this nsp3-specific peptide in at least one blood sample (across 4 time points).
None of the recovered COVID patients or uninfected controls tested positive.
The study only sampled during exercise testing.
Exercise can mobilize proteins and debris from tissues - think of it as shaking a snow globe.
So this may reflect what’s shaken loose from reservoirs, not constant circulation.
Context: Nsp3 is a multifunctional protein that:
Remodels the endoplasmic reticulum (ER) into a viral factory
Hijacks lipid metabolism to fuel replication
Interferes with mitochondrial function
Modulates innate immunity to help the virus persist
How SARS-CoV-2 turns a cell into its factory (second study):
NSP3, NSP4, NSP6 - remodel the endoplasmic reticulum (ER) into protected replication zones.
ORF8, NSP4 - hijack ER stress responses to favor the virus.
ORF3a, ORF7a - exploit autophagy, rerouting waste away from lysosomes so the cell can’t clean itself.
Damages mitochondria to weaken immunity.
Forces the cell to make extra lipids (ceramides, phosphatidic acids) for building materials and energy.
End result: a protected viral factory, an overloaded cell, damaged tissue. pubmed.ncbi.nlm.nih.gov/40295886/
Persistent nsp3 in EVs could maintain neuroinflammation, disrupt glial communication, and worsen cognitive symptoms (brain fog).
Mitochondria: nsp3 impacts the cell’s energy hubs, contributing to fatigue and post-exertional malaise (PEM).
Viral proteins packaged in EVs can bypass immune surveillance, reprogram cell metabolism, and impact the nervous system - even without active viral replication.
This is a well-documented feature in HIV, and SARS-CoV-2 appears to exploit a similar strategy.
Abbasi et al.s work offers a potential biomarker for #LongCOVID (nsp3 in EVs), but also a warning: persistent viral proteins may be active drivers of long-term symptoms - not just leftovers from infection.
Context from other research - another ORF1ab enzyme - Mpro (nsp5, the main protease) - can cleave TDP-43, a key protein for neuron health.
TDP-43 damage is linked to ALS and dementia.
If Mpro ever circulated like nsp3 fragments do here, it could pose a direct neurodegenerative risk.
Bottom line.
Detection of an nsp3-derived peptide in EVs months–years post-infection is strong evidence of ongoing viral material in the body.
Whether it’s harmless debris or an active weapon depends on the fragment’s function - and we urgently need to find out.
Abbasi et al. (2025). Possible long COVID biomarker: identification of SARS‑CoV‑2 related protein(s) in Serum Extracellular Vesicles. Infection, 2025 ?link.springer.com/article/10.100…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Even without live virus, blood serum can carry signals powerful enough to change how healthy tissue works.
A new peer-reviewed study shows serum from ME/CFS and long COVID patients can directly impair muscle function in lab-grown human muscle.
5 years in, we still don’t know exactly which factors are responsible 🧵
The team built sophisticated 3D mini-muscles from human myoblasts. These bioengineered tissues contract when electrically stimulated, much like real muscles.
Then they bathed them in serum from ME/CFS or long COVID patients and watched what happened.
The results were striking.
After just 48 hours, previously healthy muscle tissue showed:
weaker contractions,
shorter endurance,
disrupted calcium (Ca2+) regulation,
clear signs of mitochondrial stress.
In short - muscles that were working perfectly started behaving like diseased ones.
Post-COVID pulmonary fibrosis (PC19-PF) = permanent scarring of lung tissue after SARS-CoV-2 infection.
Not just leftover inflammation - it’s a distinct biological state.
Some patients improve on their own. Others? The scarring progresses. Detecting it early is critical. Review🧵
How common? Depends who you look at
Hospitalized patients: 30-40% show PF signs at 6-12 months.
General population: lower, but true numbers are unknown.
Research bias alert: the sickest patients are followed most closely, so mild cases are often missed.
Key risk factors for PC19-PF
Severe COVID (especially ICU/ventilation)
Older age
Comorbidities (COPD, diabetes, cardiovascular disease)
Earlier variants (wild-type, Delta) posed a higher risk than Omicron.
Each factor adds biological weight toward fibrosis.
Cardio-Pulmonary Features of Long COVID review.
From molecular pathways to clinical impact - and why heart and lung damage often go hand-in-hand.
Most mechanisms are variant-agnostic; prevalence numbers reflect the specific wave & vaccine context.🧵
Early imaging data was alarming.
In a JAMA Cardiology 2020 study (Wuhan strain, early 2020, pre-vaccine):
78% of recently recovered patients showed cardiac abnormalities on MRI
60% had signs of ongoing myocardial inflammation
These were not only patients with severe acute illness - many had mild initial COVID.
Histopathology tells the same story:
Endothelial damage in heart and lung microvasculature
Perivascular immune cell infiltration (lymphocytes, macrophages)
Microvascular thrombosis
SARS-CoV-2 RNA and proteins found in myocardial tissue months after infection - ongoing antigenic stimulation
New research reveals that #COVID19 can quietly damage blood vessels and disrupt red blood cell production - even in people with absolutely no symptoms. This was uncovered using a tool called an epigenetic liquid biopsy, which tracks where tiny fragments of DNA in your blood originate.🧵
Epigenetic liquid biopsy - from a small blood sample, scientists can read the DNA fragments released by dying cells and tell which tissues they came from - and even what genes were active before the cells died.
A powerful way to spot hidden damage early.
In severe COVID-19 cases, researchers observed:
Extensive death of lung cells
Heart tissue injury
Damage to blood vessel linings (endothelium)
Heightened immune activity
Increased red blood cell generation (possibly to compensate for faster cell loss)
Can COVID-19 cause lasting heart changes in children - even after a mild case?
Yes.
A new peer-reviewed study followed kids after infection.
The shocking part? Just how many still show signs of heart dysfunction years later.🧵
Even in children who had mild COVID, researchers found measurable - and persistent changes in heart function and blood pressure.
These weren’t isolated cases.
Some of the effects were detectable years after infection.
The study followed 228 children (ages 1–18) with PCR-confirmed COVID-19 in Kazakhstan.
Follow-up occurred 24-36 months after infection (2023-2024).
There was also a matched control group of 172 children with respiratory symptoms but no COVID-19.
What do we really know about COVID-19 vaccines and long COVID?
A meta-analysis from Robert Koch Institute analyzes 65 studies (5.7M people) to answer one critical question:
Do vaccines reduce the risk of long COVID when given before infection?
Short answer: Yes - but two key problems remain.🧵
Post-COVID condition (PCC; symptoms ≥3 months):
Vaccine effectiveness (VE): 41% (95% CI: 27.8–51.7%)
Long COVID (LC; symptoms ≥4 weeks):
VE: 34.1% (95% CI: 25.0–42.2%)
Effectiveness increased with dose count:
1 dose: 19%
2 doses: 43%
3 doses: 70% (based on one study)
Lower VE was observed:
in children (26%)
after Omicron infection: only 21% (CI –10% to +43%) - based on just two studies, but suggests that vaccines may be far less protective against long COVID after Omicron - especially in younger or previously exposed populations.
But two key factors limit how we interpret this data:
How long does protection last?
All included studies looked at vaccination before infection - but none analyzed VE as a function of time since vaccination.
We still don’t know if vaccines protect against long COVID 6 or more months after administration.
And that’s a major policy blind spot.
This lack of temporal analysis was explicitly acknowledged as a limitation by the authors.